A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

PMC Capital Acquires the Assets of Ransom & Randolph Company from Dentsply Sirona

February 2, 2021

PMC Capital notes that Ransom & Randolph Company, is a leading mission-critical manufacturer and supplier of specialty consumables to the global investment casting industry, serving aerospace, defense, industrial gas turbine, automotive, commercial, jewelry, dental, and art casting markets from Dentsply Sirona, Inc.

Financial terms of the transaction were not disclosed.

The divestment of Ransom & Randolph is part of Dentsply Sirona’s strategy to focus on its core business.

“We are extremely thrilled that this transaction creates an opportunity from which both sides will benefit. As Ransom & Randolph looks forward to the future, the roadmap will be to execute a growth model which includes strategic acquisition and organic growth,” says Michel Tamer, Managing Partner of PMC Capital.

“As an independent business, Ransom & Randolph will strengthen its focus on our industrial foundry, jewelry and dental lab customer base, while also remaining an important partner to Dentsply Sirona. The R&R team and I are eager to serve our customers in new and exciting ways,” says Daniel Nixon, President of Ransom & Randolph.

Founded in 1872, Ransom & Randolph is dedicated to advancing the global investment casting industry. Ransom & Randolph has provided foundries, dental labs, and jewelers with extensive process knowledge, exceptional technical expertise and innovative product technology since the 1800s. By coupling revolutionary product developments with experienced staff, manufacturing and warehousing facilities worldwide, Ransom & Randolph successfully helps customers become casting industry leaders.

CriticalPoint Partners, LLC served as Dentsply Sirona’s exclusive financial advisor for the transaction. 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy